Clin2
NCT05076617Possibly a fitEnrolling by invitation

Testing a long-acting rescue seizure medicine for prolonged seizures

Stereotypical Prolonged Seizures

Part of Brain & nervous system clinical trials.

This Phase 3 study tests the safety and side effects of Staccato alprazolam for teens and adults (12+) who have certain types of long-lasting seizures. It may help people by offering a specific medicine option aimed at stopping prolonged seizure episodes under close medical study.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
300 people
Ages
12 years and older
Study type
Interventional

Who can take part

  • Be age 12 or older when you sign consent
  • Have a study caregiver age 18+ who can watch for and recognize your seizures
  • Have diagnosed epilepsy with past “typical” prolonged seizure episodes (lasting at least a few minutes, as defined by the study)
  • Have already tried Staccato alprazolam in a prior study before screening
  • No alcohol or drug use disorder in the past year
  • Avoid certain breathing/eye/mouth conditions and specific medicines that the study says would make participation unsafe

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05077904Recruiting· Phase 3
Staccato alprazolam study for prolonged seizures in teens and adults

This Phase 3 trial tests whether staccato alprazolam can reduce and manage “prolonged seizures” that happen repeatedly in people with epilepsy. It also checks safety—especially breathing and heart-related side effects—while participants continue their usual seizure medicines.

Phoenix, Arizona
NCT06908356Recruiting· Phase 2
Testing PRAX-628 for focal or tonic-clonic seizures

This study tests an experimental pill called PRAX-628 for adults whose seizures are not fully controlled by current medications. It aims to see if the drug is safe and effective at reducing seizures.

Phoenix, Arizona
NCT05718817Enrolling by invitation· Phase 3
Long-term study of XEN1101 for people with epilepsy

This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.

Phoenix, Arizona
NCT05121324Recruiting· Phase 3
Tested higher-dose seizure medicine for children during EMS care

This trial studies the best dose of a seizure medicine for children who are actively seizing while emergency medical teams are treating them. It may help EMS crews give safer, more effective treatment during transport.

Tucson, Arizona
NCT05667142Recruiting· Phase 3
Testing an add-on drug for hard-to-control generalized convulsive seizures

This Phase 3 trial tests XEN1101 added to your current seizure medicines for people with primary generalized tonic-clonic seizures. It’s for seizures that have not fully stopped even after trying at least two appropriate medicines.

Mobile, Alabama
NCT05518578Recruiting· Phase 2
Drug trial for hard-to-control focal epilepsy with brain scar

This Phase 2 trial tests SPN-817 in adults whose seizures are still not well controlled despite trying multiple seizure medicines. It targets people with a specific type of brain finding called focal cortical dysplasia and looks at safety/tolerability and seizure outcomes over several weeks.

Jacksonville, Florida

Hear when a new Stereotypical Prolonged Seizures trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.